Dermatology & Plastic Surgery Institute Outcomes
Surgical Quality Improvement
Neurosurgery Outcomes
January 1, 2023 – December 31, 2023
The American College of Surgeons National Surgical Quality Improvement Program (ACS NSQIP®) objectively measures and reports risk-adjusted surgical outcomes based on a defined sampling and abstraction methodology. These outcomes data reflect Cleveland Clinic’s overall neurosurgery ACS NSQIP performance benchmarked against 338 participating sites.
| Neurosurgery (338 Sites) | N | Observed | Expected |
|---|---|---|---|
| 30 Day Mortality | 310 | 2.58% | 2.28% |
| 30 Day Morbidity | 310 | 12.58% | 9.20% |
| Cardiac | 310 | 0.00% | 0.58% |
| Pneumonia | 310 | 2.26% | 1.88% |
| Unplanned Intubation | 309 | 2.59% | 1.73% |
| Ventilator > 48 Hours | 308 | 3.57% | 1.43% |
| Deep Vein Thrombosis (DVT) / Pulmonary Embolusᵃ | 310 | 6.77% | 2.86% |
| Renal Failure | 310 | 0.97% | 0.41% |
| Urinary Tract Infection (UTI) | 310 | 1.29% | 1.50% |
| Surgical Site Infection (SSI) | 310 | 3.23% | 1.98% |
| Sepsis | 310 | 2.58% | 1.40% |
| C.diff Colitis | 310 | 0.32% | 0.09% |
| Unplanned Reoperation | 310 | 4.19% | 4.69% |
| Unplanned Readmission | 310 | 12.58% | 10.22% |
American College of Surgeons National Surgical Quality Improvement Program, 2024.
ACS NSQIP® Semiannual Report July 8, 2024, Chicago: American College of Surgeons.
ᵃIdentified as a statistical outlier (higher than expected) by the ACS NSQIP hierarchical model.
